Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
the Key Project of the National Natural Science Foundation of China (81530036)
Excess amounts excrete through urine without causing harm
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Label Warnings Not a sole source of nutrition and should be consumed with a nutritious diet
Adults over 50 Intrinsic factor production declines with age
The FDA did not approve BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax through this advisory process
US$ 28.63
US$ 20.13
US$ 28.91
US$ 25.80
US$ 25.38
US$ 25.08
US$ 21.81
US$ 23.66
